<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01269151</url>
  </required_header>
  <id_info>
    <org_study_id>LucERG-001</org_study_id>
    <nct_id>NCT01269151</nct_id>
  </id_info>
  <brief_title>Ranibizumab Short- and Log-term Effects on Retinal Function in wAMD</brief_title>
  <acronym>LucERG</acronym>
  <official_title>A Prospective, Non-randomized, Mono-center, Cohort Study to Evaluate the Short- and Long-term Effects of 0.5mg Intraocular Ranibizumab (Lucentis) Injections on Retinal Function in Patients With Wet Age-related Macular Degeneration During Twelve Month</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Luebeck</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Luebeck</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multifocal-electroretinoram (ERG) and microperimetry are objective criteria to asses retinal&#xD;
      function. No information besides visual acuity exist for the development of retinal function&#xD;
      during the course of wet AMD during therapy with Lucentis. The aim of our study is to&#xD;
      evaluate the value of multifocal-ERG and microperimetry as an sensitive tool and early&#xD;
      predictor of recurrence of the disease. The second goal will be to evaluate the&#xD;
      neuroprotective effects of an adequate therapy on retinal function using microperimetry and&#xD;
      multifocal-ERG during the course of wet AMD.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes of retinal function of the macula monitored by multifocal-ERG and microperimetry as measured 12 months.</measure>
    <time_frame>12 months</time_frame>
    <description>Main outcome measures are the changes of retinal function of the macula monitored by multifocal-ERG and microperimetry as measured 12 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>to document changes in best corrected visual acuity (BCVA) measured on 4 meters,</measure>
    <time_frame>12 months</time_frame>
    <description>to document changes in best corrected visual acuity (BCVA) measured on 4 meters,</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>to document changes in angiography</measure>
    <time_frame>12 months</time_frame>
    <description>to document changes in angiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>to document changes in optical coherence tomography (OCT)</measure>
    <time_frame>12 months</time_frame>
    <description>to document changes in optical coherence tomography (OCT)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Age-Related Macular Degeneration</condition>
  <condition>Retinal Function</condition>
  <arm_group>
    <arm_group_label>Lucentis (Ranibizumab)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lucentis (Ranibizumab)</intervention_name>
    <description>Ranibizumab Short- and Log-term Effects on Retinal Function measured by Multifocal-ERG and Microperimetry</description>
    <arm_group_label>Lucentis (Ranibizumab)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male and female patients above 50 years of age&#xD;
&#xD;
          2. wet age-related macular degeneration (AMD)&#xD;
&#xD;
          3. an available follow-up of 12 months&#xD;
&#xD;
          4. written informed consent&#xD;
&#xD;
          5. visual acuity of 0.1 or better&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Systemic conditions or treatments&#xD;
&#xD;
          1. history or evidence of severe cardiac disease (e.g., NYHA functional class III or IV)&#xD;
&#xD;
          2. clinical or medical history of unstable angina, acute coronary syndrome, myocardial&#xD;
             infarction or revascularization within the last 6 months&#xD;
&#xD;
          3. ventricular tachyarrythmias requiring ongoing treatment&#xD;
&#xD;
          4. History or evidence clinically significant peripheral vascular disease, such as&#xD;
             intermittent claudication or prior amputation&#xD;
&#xD;
          5. Clinically significant impaired renal or hepatic function&#xD;
&#xD;
          6. Stroke within 12 month before trial entry.&#xD;
&#xD;
          7. Known serious allergies to the fluorescein dye use in angiography&#xD;
&#xD;
          8. Known contraindications to the components of Lucentis® formulation.&#xD;
&#xD;
        Ocular concomitant conditions/ diseases&#xD;
&#xD;
          1. Active intraocular inflammation (grade trace or above) in either eye&#xD;
&#xD;
          2. Any active infection (e.g. conjunctivitis, keratitis, scleritis, uveitis,&#xD;
             endophthalmitis) in either eye&#xD;
&#xD;
          3. History of uveitis in either eye&#xD;
&#xD;
          4. Treatment with anti-angiogenic drugs (pegaptanib sodium, anecortave&#xD;
             acetate,bevacizumab, etc.) or intravitreal corticosteroids in either eye within 3&#xD;
             months prior to inclusion&#xD;
&#xD;
          5. Angle block glaucoma&#xD;
&#xD;
          6. Phthisis&#xD;
&#xD;
          7. Intraocular Pressure &lt;10mmHg&#xD;
&#xD;
          8. Macular or retinal dystrophies&#xD;
&#xD;
        Compliance/ Administrative&#xD;
&#xD;
          1. Previous participation in any clinical studies of investigational drugs (excluding&#xD;
             vitamins and minerals) within 1 month (or a period corresponding to 5 half-lives of&#xD;
             the investigational drug, whatever is longer) prior to inclusion.&#xD;
&#xD;
          2. Patients will be excluded who were younger than 50 years according of the definition&#xD;
             of age-related AMD.&#xD;
&#xD;
          3. Women of child-bearing potential, defined as all women physiologically capable of&#xD;
             becoming pregnant.&#xD;
&#xD;
          4. Pregnant or nursing (lactating) women&#xD;
&#xD;
          5. Inability to comply with study or follow-up procedures.&#xD;
&#xD;
          6. Any treatment with an investigational agent in the past 3 months any condition.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Salvatore Grisanti, M.D. Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Luebeck - Department of Ophthalmology: Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Luebeck - Department of Ophthalmology</name>
      <address>
        <city>Lübeck</city>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.uksh.de/Augenklinik_Luebeck/index.html</url>
    <description>University of Luebeck - Department of Ophthalmology - Germany</description>
  </link>
  <verification_date>April 2015</verification_date>
  <study_first_submitted>January 3, 2011</study_first_submitted>
  <study_first_submitted_qc>January 3, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 4, 2011</study_first_posted>
  <last_update_submitted>April 7, 2015</last_update_submitted>
  <last_update_submitted_qc>April 7, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 8, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Luebeck</investigator_affiliation>
    <investigator_full_name>Dr. Matthias Lueke</investigator_full_name>
    <investigator_title>Dr. med. Matthias Lüke</investigator_title>
  </responsible_party>
  <keyword>Age-Related Macular Degeneration</keyword>
  <keyword>Retinal Function</keyword>
  <keyword>multifocal-ERG</keyword>
  <keyword>Electroretinography</keyword>
  <keyword>microperimetry</keyword>
  <keyword>Lucentis</keyword>
  <keyword>Ranibizumab</keyword>
  <keyword>longterm effects</keyword>
  <keyword>best corrected visual acuity</keyword>
  <keyword>BCVA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

